PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer
Bo Liu(Union Hospital), Timothy C. Thompson(The University of Texas MD Anderson Cancer Center), Michael Sigouros(Cornell University), Dimitrios Korentzelos(University of Pittsburgh Medical Center), Patricia Troncoso(The University of Texas MD Anderson Cancer Center), Andrea Sboner(Cornell University), Himisha Beltran(Dana-Farber Cancer Institute), Paul G. Corn(Cornell University), Michael T. Tetzlaff(Hospital of the University of Pennsylvania), Guang Yang(Jinan University), Ganiraju C. Manyam(The University of Texas MD Anderson Cancer Center), Zhenyang Dong(The University of Texas MD Anderson Cancer Center), Yu Chen(Guangdong Academy of Medical Sciences), Yong Luo(Capital Medical University), Sanghee Park(Hanbat National University), Wenhui Wu(The University of Texas MD Anderson Cancer Center), Zhe Tang(Zhejiang International Studies University), Likun Li(The University of Texas MD Anderson Cancer Center), Cheng Wu(Second Military Medical University), Chuandong Geng(Baylor College of Medicine), Bradley M. Broom(The University of Texas MD Anderson Cancer Center)
Cited by 78
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k